On the other hand, the outcome of the antitumour immunity is determined by the type of the developed immune response and TILs, including NK and cytotoxic CD8+ T cells, are known to protect against tumour development and progression.49 In this regard, TILs in human biopsies are emerging as a positive prognostic factor in different solid tumours, including breast cancer.50 In addition, TDLN are used as prognostic markers in breast cancer. This evidence concerns the gene CD8A and breast carcinoma.